摘要
目的研究脂蛋白相关磷脂酶A2(LP-PLA2)在急性冠脉综合征和稳定性心绞痛患者的浓度及其临床意义。方法 选择经冠状动脉造影确诊冠心病患者83例,其中急性冠脉综合征组(ACS)48例,稳定性心绞痛组(SAP)35例;健康对照组45例,测定其脂蛋白相关磷脂酶A2(LP-PLA2)的浓度,并记录高敏C-反应蛋白(hs-CRP),白细胞(WBC)等其他临床指标,分析LP-PLA2在三组中的差异以及与其他临床指标的相关性。结果(1)LP-PLA2浓度水平在ACS组及SAP组显著高于对照组(P<0.01),ACS与SAP组间差别无统计学意义(P>0.05)(2)LP-PLA2浓度与低密度脂蛋白胆固醇(LDL-C)呈显著正相关(r=0.41,P<0.01),与高密度脂蛋白胆固醇(HDL-C)呈显著负相关(r=-0.31,P<0.01)。(3)均衡其他危险因素,LP-PLA2浓度与冠心病独立相关。结论 LP-PLA2是急性冠脉综合征和稳定性心绞痛患者的独立危险因素,可能在预测ACS和SAP风险及其治疗方面具有重要意义。
Objective To investigate the correlation between plasma lipoprotein-associated phospholipase A2（LP-PLA2） mass and acute coronary syndrome （ACS） or stable angina pectoris （SAP）. Methods Every patient was enrolld by coronary angiography （CAG）. Eighty - three cases of patients were divided into three group according to clinical diagnosis： ACS group （48 cases）, SAP group （35 cases）, Control group （45 eases）. The LP-PLA2 mass,hypersensitive creactive protein （hsCRP） etc were measured. Results （1） Plasma LP-PLA2 mass was significantly higher in the ACS group and SAP group than that in the control group（P〈0.01）, while there were no differences between the ACS patients and SAP patients （P〉0.05）. （2）LP-PLA2 mass showed a great positively correlation with LDL-C（r=0.41,P〈0.O／01） and a significant negatively with HDL-C（r=-0.31,P〈0.01）. （3）LP-PLA2 mass were correlated independently with CHD. Conclusion LP-PLA2 could be a independent risk factor and a predictor for ACS and SAP patients and it may provide a new target for the treatment of CHD.
出处
《中国现代医生》
2011年第12期6-8,共3页
China Modern Doctor
